Business
Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
According to the report, at least 17 of this year’s 28 new drug shortages “are directly or indirectly prompted by events the current COVID-19 pandemic has brought on,” which includes the increased demand for anesthetics and other drugs used to facilitate intubation.
In an interview this morning with CNN, Dr. Anthony Fauci said the government will help finance Phase III studies of three vaccine candidates.
Biogen announced new data from the NURTURE trial of pre-symptomatic patients with spinal muscular atrophy (SMA).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
Charles Lieber, the former chair of Harvard University’s Chemical Biology Department, was indicted by a federal grand jury this week on two counts of making false statements.
The collaboration will focus on the development of three of Genmab’s bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.
Fauci, a longtime infectious disease expert, said COVID-19 is the stuff of nightmares in the way it has quickly spread across the globe, infected millions of people and contributed to the deaths of more than 408,000 people.
The healthcare system is innovating to address the pain points the pandemic revealed. Specifically, it is becoming more proactive, preventative and personalized.
One day, cell and gene therapies will be as common as small molecules and antibody-based therapies are today, according to panelists at BIO’s June 8 virtual session, “The Next Generation of Medicine: Cell Therapies, Gene Therapies and Beyond.”
The annual Biotechnology Innovation Organization meeting kicked off Monday with the proverbial passing of the baton from longtime head Jim Greenwood to Michelle McMurry-Heath, who was tapped to take over the organization last month.